Conflict of interest: M.A. Mall reports grants from German Ministry for Education and Research (BMBF), German Research Foundation (DFG), German Innovation Fund and Vertex Pharmaceuticals, consultancy fees from Abbvie, Antabio, Arrowhead, Boehringer Ingelheim, Enterprise Therapeutics, Kither Biotec, Prieris, Recode, Santhera, Splisense and Vertex Pharmaceuticals, lecture honoraria from Vertex Pharmaceuticals, travel support from Boehringer Ingelheim and Vertex Pharmaceuticals, advisory board participation with Abbvie, Antabio, Arrowhead, Boehringer Ingelheim, Enterprise Therapeutics, Kither Biotec, Pari and Vertex Pharmaceuticals, and a leadership role as Fellow of ERS (FERS), outside the submitted work. M.O. Wielpütz reports grants from German Ministry for Education and Research (BMBF) and Vertex Pharmaceuticals, consulting fees from Boehringer Ingelheim and Vertex Pharmaceuticals, and leadership roles with ESTI, IWPFI and DRG, outside the submitted work.